The Surging Tides Of Global Medical Cannabis Markets
You may not see it or even hear about it but have no doubts: an enormous regulatory framework tsunami pushing global medical cannabis is happening right now.
Two Major Transatlantic Medical Cannabis Waves Start 2024
In the first two months of 2024, two significant catalytic events occurred, the likes of which have not been seen since California first went recreational in 2016, starting the United States’ industrial cannabis boom. Germany, the largest and most powerful country in Europe, decriminalized cannabis and, most importantly, took cannabis off the narcotics registry.
Additionally, a top U.S. health organization — the Health and Human Services (HHS) — wrote a recommendation letter and corresponding 252-page report to the Drug Enforcement Agency (DEA) after two decades of observing medical and recreational cannabis, concluding that not only is cannabis safe but further acknowledging cannabis is effective for at “least” 15 medical indications including neuropathic pain.
Ripple Effects: US-German Cannabis Movements Grab Global Health Attention
One may argue the relevance of these U.S. and German-based decisions in light of each country’s internal debates on cannabis. However, there certainly are new discussions to be had, given these two significant advancements in medical cannabis access.
The U.S. HHS/DEA letter and report are a turning point on which regulators can base their decisions. Because there are few clinical trials to determine policy, a vast HHS-driven observational study is a substantial piece of data to rely on. There is also a similar Health Canada yearly report that details in 200 …